Press releases

2020  |  2019  |  2018  |  All
September 15, 2020
Compass Therapeutics, Inc. Provides Corporate Update
August 24, 2020
Compass Therapeutics Announces Publication in the Journal Science of Preclinical Data Supporting the Potential of CTX-2026, a Novel Antibody to the Butyrophilin BTN3A1, in Ovarian Cancer Tumor Models
June 23, 2020
Compass Therapeutics Completes Reverse Merger and Closes $60 Million Private Placement

Presentations and publications

View all
March 12, 2020 | JCI Insight
Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity
November 12, 2019 | SITC 2019
CTX-8371, a Novel Bispecific Targeting both PD-1 and PD-L1, is more Potent than Combination anti-PD-1 and PD-L1 Therapy and Provides Enhanced Protection from Tumors in vivo
November 12, 2019 | SITC 2019
A novel class of Innate Cell Engagers targeting NKp30

In the news

View all
September 17, 2020
Checkpoint Inhibitor CTX-2026 Shows Promising Efficacy in Preclinical Study
August 20, 2020
Ayala Pharmaceuticals Announces the Appointment of Vered Bisker-Leib, Ph.D. To Its Board of Directors
April 6, 2020
Compass Therapeutics’ immuno-oncology prospect clears solid tumors in mice

Events

PEGS Europe
November 9 – 13
Lisbon, Portugal
SITC
November 10 – 15
National Harbor, MD
Stifel Healthcare Conference
November 17 – 18
New York, NY
Piper Sandler 32nd Annual Healthcare Conference
December 1 – 3
New York, NY
ASH
December 5 – 8
San Diego, CA